The clonoSEQ® Watch Registry


Trial ID: NCT04545333


This is a prospective, multicenter, observational study of adult patients with a diagnosis of acute lymphoblastic leukemia (ALL), multiple myeloma (MM), chronic lymphocytic leukemia (CLL), or non-Hodgkin lymphoma (NHL). This study will enroll up to 528 patients in up to 50 sites in the United States and collect data with regard to use of the clonoSEQ MRD assay in the management of lymphoid malignancies.

Official Title

Real World Observational Study Using clonoSEQ® Next Generation Sequencing in Hematologic Malignancies: The 'Watch' Registry

Stanford Investigator(s)

Lori Muffly
Lori Muffly

Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)


Inclusion Criteria:

   1. Patients must be able to provide written informed consent

   2. A decision has been made by the treating provider to use the clonoSEQ Assay as part of
   routine clinical care

   3. Age ≥ 18 years;

   4. Documented hematologic malignancy (any of the below):

      1. MM

      2. ALL (B and T-cell subtypes)

      3. B-cell NHL (all sub types)

      4. CLL

      5. Other lymphoid malignancies (upon review and approval by study chair)

Exclusion Criteria:

Patients must not meet any of the following criteria in order to be enrolled into the

   1. Concurrent enrollment in a clinical trial where treatment decisions and patterns are
   dictated per protocol

   2. A decision has been made by the treating provider to not use the clonoSEQ Assay as
   part of routine clinical care


diagnostic test: clonoSEQ Assay


Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Janet McDowell